BACKGROUND/AIMS: Acetaminophen overdose causes hepatotoxicity mediated by toxic metabolites generated through the cytochrome P450 enzyme. The objective of this study was to investigate whether acetaminophen (AAP) can enhance cisplatin (CDDP) cytotoxicity against human hepatocarcinoma and hepatoblastoma cells in vitro and whether this effect can be prevented by N-acetylcysteine (NAC). METHODS: In vitro studies (glutathione [GSH] level, cell viability, and immunoblot assays) were performed using human hepatocarcinoma and hepatoblastoma cells cultured in AAP, CDDP, and the combination of both with or without delayed NAC administration. The pharmacology and toxicology of high-dose AAP in rats were also examined. RESULTS: Acetaminophen decreased GSH levels in liver cancer cells in a dose- and time-dependent manner. Acetaminophen combined with CDDP had enhanced cytotoxicity over CDDP alone. The cytotoxicity caused by AAP plus CDDP was decreased by NAC, with the effectiveness being time-dependent. The GSH level was lowered in the liver but not in the blood or the brain in rats treated with a high dose of AAP (1000 mg/kg). The expression of CYP2E1 protein, a key cytochrome P450 enzyme, varies among species but is not correlated to AAP sensitivity in liver cancer cells. CONCLUSIONS: Our results suggest that a chemotherapeutic regimen containing both AAP and CDDP with delayed NAC rescue has the potential to enhance chemotherapeutic efficacy while decreasing adverse effects. This would be a promising approach particularly for hepatoblastomas regardless of cellular CYP2E1 protein level but could also be beneficial in other malignancies.
BACKGROUND/AIMS: Acetaminophenoverdose causes hepatotoxicity mediated by toxic metabolites generated through the cytochrome P450 enzyme. The objective of this study was to investigate whether acetaminophen (AAP) can enhance cisplatin (CDDP) cytotoxicity against humanhepatocarcinoma and hepatoblastoma cells in vitro and whether this effect can be prevented by N-acetylcysteine (NAC). METHODS: In vitro studies (glutathione [GSH] level, cell viability, and immunoblot assays) were performed using humanhepatocarcinoma and hepatoblastoma cells cultured in AAP, CDDP, and the combination of both with or without delayed NAC administration. The pharmacology and toxicology of high-dose AAP in rats were also examined. RESULTS:Acetaminophen decreased GSH levels in liver cancer cells in a dose- and time-dependent manner. Acetaminophen combined with CDDP had enhanced cytotoxicity over CDDP alone. The cytotoxicity caused by AAP plus CDDP was decreased by NAC, with the effectiveness being time-dependent. The GSH level was lowered in the liver but not in the blood or the brain in rats treated with a high dose of AAP (1000 mg/kg). The expression of CYP2E1 protein, a key cytochrome P450 enzyme, varies among species but is not correlated to AAP sensitivity in liver cancer cells. CONCLUSIONS: Our results suggest that a chemotherapeutic regimen containing both AAP and CDDP with delayed NAC rescue has the potential to enhance chemotherapeutic efficacy while decreasing adverse effects. This would be a promising approach particularly for hepatoblastomas regardless of cellular CYP2E1 protein level but could also be beneficial in other malignancies.
Authors: K Järvinen; P Pietarinen-Runtti; K Linnainmaa; K O Raivio; C M Krejsa; T Kavanagh; V L Kinnula Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-04 Impact factor: 5.464
Authors: D Casper; R Lekhraj; U S Yaparpalvi; A Pidel; W A Jaggernauth; P Werner; S Tribius; J D Rowe; P A LaSala Journal: J Neurooncol Date: 2000 Impact factor: 4.130
Authors: Jedd D Wolchok; Linda Williams; John T Pinto; Martin Fleisher; Susan E Krown; Wen-Jen Hwu; Philip O Livingston; Christine Chang; Paul B Chapman Journal: Melanoma Res Date: 2003-04 Impact factor: 3.599
Authors: G Perilongo; E Shafford; R Maibach; D Aronson; L Brugières; P Brock; M Childs; P Czauderna; G MacKinlay; J B Otte; J Pritchard; R Rondelli; M Scopinaro; C Staalman; J Plaschkes Journal: Eur J Cancer Date: 2004-02 Impact factor: 9.162
Authors: Alexander J Neuwelt; Tam Nguyen; Y Jeffrey Wu; Andrew M Donson; Rajeev Vibhakar; Sujatha Venkatamaran; Vladimir Amani; Edward A Neuwelt; Louis B Rapkin; Nicholas K Foreman Journal: Pediatr Blood Cancer Date: 2013-08-17 Impact factor: 3.167
Authors: Penelope R Brock; Kristin R Knight; David R Freyer; Kathleen C M Campbell; Peter S Steyger; Brian W Blakley; Shahrad R Rassekh; Kay W Chang; Brian J Fligor; Kaukab Rajput; Michael Sullivan; Edward A Neuwelt Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Jie Li; Donglan Zhang; Kathleen M Ward; George C Prendergast; Iraimoudi S Ayene Journal: Toxicol In Vitro Date: 2012-01-31 Impact factor: 3.500